1. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients

   • Jane E Latz
   • Ajai Chaudhary
   • Robert D Johnson

   Original Article 02 December 2005 Pages: 401 - 411

   

2. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

   • Jane E Latz
   • Mats O Karlsson
   • Robert D Johnson

   Original Article 02 December 2005 Pages: 412 - 426

   

3. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy

   • Jane E. Latz
   • James J. Rusthoven
   • Robert D. Johnson

   Original Article 02 December 2005 Pages: 427 - 435

   

4. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma

   • Seok Jin Kim
   • Hee Yun Seo
   • Jun Suk Kim

   Original Article 28 July 2005 Pages: 436 - 442

   

5. Interpreting cell cycle effects of drugs: the case of melphalan

   • Monica Lupi
   • Paolo Cappella
   • Paolo Ubezio

   Original Article 30 September 2005 Pages: 443 - 457

   

6. A liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of actinomycin-D and vincristine in children with cancer

   • Jeffrey M. Skolnik
   • Jeffrey S. Barrett
   • Peter C. Adamson

   Original Article 27 September 2005 Pages: 458 - 464

   

7. Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers

   • Ramesh K. Ramanathan
   • Marwan Fakih
   • Merrill J. Egorin

   Original Article 25 August 2005 Pages: 465 - 474

   

8. Development and validation of limited sampling models for topotecan lactone pharmacokinetic studies in children

   • P. Kellie Turner
   • Lisa C. Iacono
   • Clinton F. Stewart

   Original Article 27 July 2005 Pages: 475 - 482

   

9. Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro

   • Jocelyn L Carr
   • Malcolm D Tingle
   • Mark J McKeage

   Original Article 20 September 2005 Pages: 483 - 490

   

10. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells

    • Maria Serova
    • Fabien Calvo
    • Eric Raymond

    Original Article 02 August 2005 Pages: 491 - 499

    

11. Pharmacokinetics and phototoxicity of purpurin-18 in human colon carcinoma cells using liposomes as delivery vehicles

    • Sulbha Sharma
    • Alok Dube
    • Pradeep K Gupta

    Original Article 02 August 2005 Pages: 500 - 506

    

12. Apoptosis induced by glycoprotein (150-kDa) isolated from Solanum nigrum L. is not related to intracellular reactive oxygen species (ROS) in HCT-116 cells

    • Sei-Jung Lee
    • Kye-Taek Lim

    Original Article 06 October 2005 Pages: 507 - 516

    

13. Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells

    • Michelutti Angela
    • Stocchi Raffaella
    • Damiani Daniela

    Original Article 05 July 2005 Pages: 517 - 524

    

14. Antiproliferation and radiosensitization of caffeic acid phenethyl ester on human medulloblastoma cells

    • Yi-Hsien Lin
    • Jen-Hwey Chiu
    • Sang-Hue Yen

    Original Article 20 September 2005 Pages: 525 - 532

    

15. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

    • Monika Jermann
    • Rolf A Stahel
    • Miklos Pless

    Original Article 29 July 2005 Pages: 533 - 539

    

16. Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer

    • Silwan Chedid
    • Edgardo Rivera
    • Massimo Cristofanilli

    Original Article 29 September 2005 Pages: 540 - 544